← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일

현재 선택: 1개 · 임상 갱신 필요 1개

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

API CSV14행 · 1개 프로그램
OverviewToxicologyClinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
ADCStandard DatabasestalePreclinical
disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin and Cisplatin)
RemeGen·Uterine Cervical Neoplasms
13 trials
Overview
Program
Disitamab Vedotin and Cisplatin
Overview
Company
RemeGen
Overview
Modality
ADC
Overview
Target
Uterine Cervical Neoplasms
Overview
Indication
Uterine Cervical Neoplasms
Overview
Phase
PRECLINICAL
Overview
Status
RECRUITING
Overview
Content status
Standard Database
Overview
Data Confidence
Data Confidence · Medium
Overview
Development Signal
Development Signal · Watch
Overview
Approval status
Investigational
Toxicology
Major finding
Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer.. Human epidermal growth factor receptor 2 (HER2)-directed antibody-drug conjugate monotherapy has shown preliminary clinical efficacy in patients with chemotherapy-refractory HER2-positive locally advanced or metastatic urothelial cancer. Previous data showed promising antitumor activity and safety of HER2-specific d…
Clinical
Safety signal
Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer.. Human epidermal growth factor receptor 2 (HER2)-directed antibody-drug conjugate monotherapy has shown preliminary clinical efficacy in patients with chemotherapy-refractory HER2-positive locally advanced or metastatic urothelial cancer. Previous data showed promising antitumor activity and safety of HER2-specific d…
Clinical
Program phase
PRECLINICAL